In 51 participants at cardiovascular risk with or without type 2 diabetes, 12 weeks of dapagliflozin reduced arterial stiffness vs placebo (placebo-adjusted aortic augmentation index -7.4%); measured GFR fell by 5.8 mL/min per 1.73m2.
RCTn = 51
Sridhar et al. Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial